|Assessment Status||Assessment Process Complete|
|Indication||For the treatment of adults with castration resistant prostate cancer, symptomatic bone metastases and no known visceral metastases. It is for use in the hospital setting.|
|Rapid review commissioned||28/11/2013|
|Rapid review completed||23/12/2013|
|Rapid review outcome||Full Pharmacoeconomic Evaluation Recommended|
|Full submission received from Applicant||11/04/2014|
|NCPE assessment completed||12/12/2014|
|NCPE assessment outcome||Reimbursement not Recommended|
The NCPE does not recommend reimbursement of radium-223 at the submitted price.
The HSE has approved reimbursement following confidential price negotiations December 2015.